Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

TRICAV-II Pivotal: TRIcvalve biCAVal ventilsystem til svær tricuspid regurgitation. (TRICAV-II)

12. november 2026 opdateret af: P+F Products + Features USA Inc.

Et prospektivt, multicenter, randomiseret, klinisk forsøg med TricValve Transcatheter Bicaval Valve System hos personer med svær tricuspid regurgitation (TR).

Pivotal trial to evaluate the safety and effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System.

Studieoversigt

Detaljeret beskrivelse

The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

780

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • University of Alabama
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85013
        • St. Joseph's Hospital and Medical Center
    • California
      • Sacramento, California, Forenede Stater, 95817
        • UC Davis Health
      • San Diego, California, Forenede Stater, 92037
        • Scripps Memorial Hospital La Jolla
      • San Francisco, California, Forenede Stater, 94143
        • UCSF
      • San Jose, California, Forenede Stater, 94118
        • Kaiser Permanente
        • Ledende efterforsker:
          • Andrew Rassi, MD
        • Kontakt:
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • MedStar Washington Hospital Center (MWHC)
        • Kontakt:
          • Erin Collins
        • Ledende efterforsker:
          • Toby Rogers, MD
    • Florida
      • Delray Beach, Florida, Forenede Stater, 33484
        • Delray Medical Center
      • Largo, Florida, Forenede Stater, 33770
      • Tampa, Florida, Forenede Stater, 33606
        • Tampa General Hospital
    • Illinois
      • Glenview, Illinois, Forenede Stater, 60026
        • Endeavor Health
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46260
        • Ascension Medical Group St. Vincent The Heart Center of Indiana
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66103
        • University of Kansas Medical Center
    • Louisiana
      • Houma, Louisiana, Forenede Stater, 70360
        • Cardiovascular Institute of the South
        • Ledende efterforsker:
          • Peter Fail, MD
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hospital
      • Burlington, Massachusetts, Forenede Stater, 01805
        • Lahey Hospital & Medical Center
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55407
        • Minneapolis Heart Institute Foundation
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64111
        • Saint Luke's Mid America Heart Institute
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University of St Louis
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Hackensack University Medical Center
    • New York
      • Manhasset, New York, Forenede Stater, 11030
        • Northwell Hospital
      • The Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Cleveland Clinic
        • Ledende efterforsker:
          • Rishi Puri, MD
      • Columbus, Ohio, Forenede Stater, 43214
        • Riverside Methodist Hospital
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health
        • Ledende efterforsker:
          • Firas Zahr, MD
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • MUSC
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Houston Methodist
      • Houston, Texas, Forenede Stater, 77030
        • University of Texas (Memorial Hermann)
      • Plano, Texas, Forenede Stater, 75093
        • Baylor Scott & White Medical
    • Utah
      • Murray, Utah, Forenede Stater, 84107
        • Intermountain Heart Institute - Intermountain Medical Center
        • Ledende efterforsker:
          • Brian Whisenant, MD
        • Kontakt:
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22903
        • UVA School of Medicine
      • Norfolk, Virginia, Forenede Stater, 23507
        • Sentara Healthcare
      • Roanoke, Virginia, Forenede Stater, 24014
        • Carilion Clinic

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Eligibility Criteria for Randomized Cohort:

Inclusion Criteria:

  1. Age between 18 years and 85 years old, at the time of signing the informed consent.
  2. Severe tricuspid regurgitation (TR) and Caval Reflux (CR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab. TVARC criteria will be used for the definition of TR severity.
  3. NYHA Class II-III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
  4. Adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team at the time of TR assessment for eligibility (TTE). OMT includes stable oral diuretic medications.
  5. High risk for open surgery and is appropriate for transcatheter tricuspid therapies according to the local heart team.
  6. Patient is unsuitable for approved transcatheter therapies and is eligible for the TricValve procedure, based on review of screening/baseline data and imaging core lab measurements by Central Screening Committee.
  7. For females of childbearing potential, negative pregnancy test.
  8. Capable and willing to provide signed informed consent

Exclusion Criteria:

CONCOMITANT PROCEDURES

  1. Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.

  2. Patient requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.

    CARDIOVASCULAR CONDITIONS

  3. LVEF ≤ 30% on echocardiography.

  4. Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.

  5. Severe right ventricular dysfunction.

  6. Cardiac amyloidosis.

  7. Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.

  8. Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to the TricValve procedure.

  9. Hemodynamically significant pericardial effusion.

  10. Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.

  11. Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure).

  12. Presence of significant congenital or acquired heart disease such as RV dysplasia, arrhythmogenic RV or other conditions that could interfere with the TricValve procedure.

    ALLERGIES / INTOLERANCE

  13. Any known allergy or hypersensitivity to nitinol, bovine tissue, or contrast media that cannot be adequately treated with pre-medication.

  14. Unable to tolerate anticoagulation/antiplatelet therapy

    COMORBIDITIES

  15. Any known life-threatening condition with an estimated life span of less than 12 months.

  16. Platelet count < 75,000/mm3

  17. Child-Pugh Severity Class C (10-15 points).

  18. Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.

  19. Endocarditis or active/ongoing infection requiring antibiotics.

  20. Unable to walk at least 100 meters in a 6-minute walk test.

  21. Known bleeding or clotting disorders or patient refuses blood transfusion.

  22. Active gastrointestinal (GI) bleeding within 3 months of TricValve procedure.

  23. Prior Malignancy: this study excludes participants at material risk of near-term cancer-related morbidity/mortality that could confound 12-month outcomes. This study allows the inclusion of fully treated, remote malignancies with documented No Evidence of Disease (NED)" criteria

    a. History of any malignancy within 5 years prior to randomization or any active malignancy, except: i. Adequately treated non-melanoma skin cancer (basal or squamous cell) with no evidence of disease, or ii. Carcinoma in situ (e.g., cervical, breast DCIS) treated with curative intent and no evidence of disease.

    b. Participants with a prior malignancy diagnosed >5 years before randomization are eligible if they meet all of the "No Evidence of Disease (NED)" criteria as specified below: i. No signs/symptoms of cancer on history and physical exam per standard of care; ii. No radiologic evidence of disease on surveillance imaging if such imaging is routinely indicated for that tumor type (not protocol-mandated); iii. Tumor markers (if applicable for that cancer) not suggestive of recurrence (e.g., stable/undetectable within site's lab reference and oncologist's judgment); iv. No active anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy, radiotherapy) and none planned; v. Treating oncologist's attestation (or primary physician if oncology follow-up is complete) that the participant is disease-free and appropriate for participation.

    GENERAL EXCLUSIONS

  24. Use or participation in other investigational device or drug study in which the patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.

  25. Any other condition that would preclude the ability to meet study requirements in the opinion of the investigator.

  26. Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up

  27. Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.

Eligibility Criteria for Single Arm Cohort:

Inclusion Criteria:

  1. Age > 85 years.
  2. NYHA Class III-IV, on intravenous inotropes, IABP or LVAD.
  3. LVEF ≤ 30% on echocardiography.
  4. Severe RV dysfunction.
  5. Severe pulmonary hypertension (PH), defined as Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or mean Pulmonary Artery Pressure (mPAP >35) by right heart catheterization.
  6. Renal insufficiency: eGFR between 25 and 30 mL/min/ 1.73 m² or on chronic renal replacement therapy.
  7. Patient unable to walk a minimum distance of 100 mt during 6 minute walk test.
  8. Prior malignancy not meeting the requirements applied for the Randomized Cohort, specified in Exclusion Criterion #23.
  9. Comorbidities precluding inclusion in the Randomized Cohort (exclusion criteria #15 to #24).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: TricValve System + Optimal medical therapy (OMT)

Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation.

• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

Andre navne:
  • Heterotopic caval valve implantation (CAVI)

Optimal medical therapy

Andre navne:
  • OMT
Aktiv komparator: Optimal medical therapy (OMT) Alone

OMT alone in patients with caval reflux and tricuspid regurgitation

Optimal medical therapy

Andre navne:
  • OMT
Eksperimentel: TricValve Single Arm Registry

Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization

• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

Andre navne:
  • Heterotopic caval valve implantation (CAVI)

Optimal medical therapy

Andre navne:
  • OMT

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Randomized Cohort: Caval Reflux (CR) grade reduction
Tidsramme: 6 months

Reduction in Caval Reflux (CR) assessed by the echocardiography core laboratory. The CR will be assessed using the 3-grade scale: Grade 1 (no reflux, reflux extending for less than 1 cm below the diaphragm), Grade 2 ( reflux extending for less than 3 cm), Grade 3 (reflux of 3 cm or more). Lower grades of CR are better.

6 months
Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
Tidsramme: 6 months

Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

6 months
Randomized Cohort: Rate of Major Adverse Events (MAE)
Tidsramme: 30 days

Rate of Major Adverse Events (MAE) in experimental arm (TricValve + OMT)

30 days
Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv
Tidsramme: 1 year

Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

1 year
Registry Cohort: Rate of Major Adverse Events (MAE)
Tidsramme: 30 days

Rate of Major Adverse Events (MAE) in single arm registry

30 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs
Tidsramme: 1 year

Rate of Major Adverse Events

1 year
Randomized Cohort: All-Cause mortality and Cardiovascular Mortality
Tidsramme: 6 months and 1 year

Number of deaths from any cause as well as cardiovascular events

6 months and 1 year
Randomized Cohort: Heart Failure Hospitalizations (HFH)
Tidsramme: 6 months and 1 year

Number of Heart Failure Hospitalizations and worsening HF events without hospitilization

6 months and 1 year
Randomized Cohort: RVAD Implantation or Heart Transplant
Tidsramme: 6 months and 1 year

Number of patients requiring RVAD Implantation or Heart Transplant

6 months and 1 year
Randomized Cohort: Atrial Fibrillation
Tidsramme: 1 year

New onset of atrial fibrillation

1 year
Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .
Tidsramme: 6 months and 1 year

Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

6 months and 1 year
Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)
Tidsramme: 6 months and 1 year

Reduction of at least 1 class from baseline. The NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

6 months and 1 year
Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).
Tidsramme: 6 months and 1 year

Improvement of 6-minute walk distance of at least 30 meters from baseline.

6 months and 1 year
Registry Cohort: Heart Failure Hospitalization
Tidsramme: 1 year

Comparison of the 12-month post-procedure HFH rate with the 12-month pre-procedure rate

1 year
Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).
Tidsramme: 1 year

Change from baseline to 12 months. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

1 year
Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs
Tidsramme: 1 year

Rate of Major Adverse Events

1 year
Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality
Tidsramme: 6 months and 1 year

Number of deaths from any cause as well as cardiovascular events

6 months and 1 year
Roll-In Cohort: Heart Failure Hospitalizations (HFH)
Tidsramme: 6 months and 1 year

Number of Heart Failure Hospitalizations and worsening HF events without hospitalization

6 months and 1 year
Roll-In Cohort: RVAD Implantation or Heart Transplant
Tidsramme: 6 months and 1 year

Number of patients requiring RVAD Implantation or Heart Transplant

6 months and 1 year
Roll-In Cohort: Atrial Fibrillation
Tidsramme: 1 year

New onset of atrial fibrillation

1 year
Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).
Tidsramme: 6 months and 1 year

Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life

6 months and 1 year
Roll-In Cohort: New York Heart Association (NYHA) functional class
Tidsramme: 6 months and 1 year

Reduction of at least 1 class from baseline. NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

6 months and 1 year
Roll-In Cohort: 6-minute walk test (6MWT).
Tidsramme: 6 months and 1 year

Improvement of 6-minute walk distance of at least 30 meters from baseline.

6 months and 1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. november 2028

Studieafslutning (Anslået)

1. november 2032

Datoer for studieregistrering

Først indsendt

7. juni 2024

Først indsendt, der opfyldte QC-kriterier

12. juni 2024

Først opslået (Faktiske)

14. juni 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CTP-TRIC-005-II

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner